These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Non-small cell lung cancer in never smokers as a representative 'non-smoking-associated lung cancer': epidemiology and clinical features. Yano T, Haro A, Shikada Y, Maruyama R, Maehara Y. Int J Clin Oncol; 2011 Aug; 16(4):287-93. PubMed ID: 21562939 [Abstract] [Full Text] [Related]
24. The impact of cigarette smoking on the frequency of and qualitative differences in KRAS mutations in Korean patients with lung adenocarcinoma. Kim HR, Ahn JR, Lee JG, Bang DH, Ha SJ, Hong YK, Kim SM, Nam KC, Rha SY, Soo RA, Riely GJ, Kim JH, Cho BC. Yonsei Med J; 2013 Jul; 54(4):865-74. PubMed ID: 23709419 [Abstract] [Full Text] [Related]
25. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Kim HR, Lim SM, Kim HJ, Hwang SK, Park JK, Shin E, Bae MK, Ou SH, Wang J, Jewell SS, Kang DR, Soo RA, Haack H, Kim JH, Shim HS, Cho BC. Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756 [Abstract] [Full Text] [Related]
29. Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity. Ko SJ, Lee YJ, Park JS, Cho YJ, Yoon HI, Chung JH, Kim TJ, Lee KW, Kim K, Jheon S, Kim H, Lee JH, Lee CT. BMC Cancer; 2014 May 03; 14():312. PubMed ID: 24885886 [Abstract] [Full Text] [Related]
30. Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute study. Serizawa M, Koh Y, Kenmotsu H, Isaka M, Murakami H, Akamatsu H, Mori K, Abe M, Hayashi I, Taira T, Maniwa T, Takahashi T, Endo M, Nakajima T, Ohde Y, Yamamoto N. Cancer; 2014 May 15; 120(10):1471-81. PubMed ID: 24700479 [Abstract] [Full Text] [Related]
32. Impact of smoking status and pathologic type on epidermal growth factor receptor mutations in lung cancer. Huang YS, Yang JJ, Zhang XC, Yang XN, Huang YJ, Xu CR, Zhou Q, Wang Z, Su J, Wu YL. Chin Med J (Engl); 2011 Aug 15; 124(16):2457-60. PubMed ID: 21933587 [Abstract] [Full Text] [Related]
33. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer. Wen S, Dai L, Wang L, Wang W, Wu D, Wang K, He Z, Wang A, Chen H, Zhang P, Dong X, Dong YA, Wang K, Yao M, Wang M. Oncologist; 2019 Nov 15; 24(11):e1070-e1081. PubMed ID: 30902917 [Abstract] [Full Text] [Related]
34. EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology. Thomas De Montpréville V, Ghigna MR, Lacroix L, Lemoine A, Besse B, Mercier O, Fadel É, Dorfmuller P, Le Chevalier T, Institut d’Oncologie Thoracique. Pathol Res Pract; 2017 Jul 15; 213(7):793-798. PubMed ID: 28554746 [Abstract] [Full Text] [Related]
35. Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion. Wu SG, Liu YN, Yu CJ, Yang JC, Shih JY. Genes Chromosomes Cancer; 2018 Oct 15; 57(10):513-521. PubMed ID: 30107055 [Abstract] [Full Text] [Related]
39. How and when to use genetic markers for nonsmall cell lung cancer. Lazarus DR, Ost DE. Curr Opin Pulm Med; 2013 Jul 15; 19(4):331-9. PubMed ID: 23715289 [Abstract] [Full Text] [Related]